CLSD
Clearside Biomedical Inc

5,131
Mkt Cap
$20.05M
Volume
36,392.00
52W High
$17.10
52W Low
$3.32
PE Ratio
-0.70
CLSD Fundamentals
Price
$3.69
Prev Close
$3.83
Open
$3.78
50D MA
$4.12
Beta
1.02
Avg. Volume
30,232.26
EPS (Annual)
-$6.98
P/B
-0.41
Rev/Employee
$52,000.00
Loading...
Loading...
News
all
press releases
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -5.26% and +15.42%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
More News
News Placeholder
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates
ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of -11.76% and +35.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates
Clearside Biomedical (CLSD) delivered earnings and revenue surprises of +50.00% and +87.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of -14.29% and -76.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know
Zacks·6mo ago
News Placeholder
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
Zacks·6mo ago
News Placeholder
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Zacks·6mo ago
News Placeholder
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
chainwire·6mo ago
News Placeholder
Clearside Biomedical's CLS-AX Shows Promise in Phase 2b Trials, Yi Chen Maintains Buy Rating with $5 Price Target
Clearside Biomedical (CLSD Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H...
TipRanks Financial Blog·1y ago
News Placeholder
Buy Rating Affirmed for Clearside Biomedical on Promising Phase 3 Results and Innovative Drug Delivery System
H.C. Wainwright analyst Yi Chen has reiterated their bullish stance on CLSD stock, giving a Buy rating today. Yi Chen has given his Buy rating due...
TipRanks Financial Blog·1y ago

Latest CLSD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.